keyword
https://read.qxmd.com/read/38706894/hmga1-is-a-prognostic-biomarker-and-correlated-with-glycolysis-in-lung-adenocarcinoma
#61
JOURNAL ARTICLE
Yu Ma, XiaoYu Ma, BuLin Du, XueNa Li, YaMing Li
Purpose: Lung cancer is one of the leading causes with high morbidity and mortality. High mobility group A1 (HMGA1) protein participates in the process of tumorigenesis. This study seeks to explore the specific role of HMGA1 in prognostic value based on The Cancer Genome Atlas (TCGA) database of Lung adenocarcinoma (LUAD) and glycolysis progression in LUAD cells. Patients and Methods: In this research, we compared HMGA1 mRNA expression between tumor tissues and normal samples and evaluated the correlations with clinical characteristics in LUAD patients based on the data of TCGA database...
2024: Journal of Cancer
https://read.qxmd.com/read/38706347/blocking-lncrna-hcg18-re-sensitizes-taxol-resistant-lung-cancer-cells-to-taxol-through-modulating-the-mir-34a-5p-hdac1-axis
#62
JOURNAL ARTICLE
Fujun Zhang, Juan Wang, Haoyu Li, Xiaoyu Luo, Qiuyue Xu, Lin Liu, Yunmin Xu, Kai Yang, Zijie Liu, Rong Gong
Lung cancer is one of the most frequently diagnosed cancers worldwide, associated with a poor survival rate. Taxol (Paclitaxel) is commonly used as a chemotherapeutic treatment for advanced lung cancers. While Taxol has improved clinical outcomes for lung cancer patients, a significant number of them develop resistance to Taxol, resulting in treatment failure. The role of the long noncoding RNA HCG18 in lung cancer and Taxol resistance has not yet been fully understood. To investigate this, we examined the expression of HCG18 and miR-34a-5p in lung tumors and normal lung tissues using qRT-PCR...
May 6, 2024: Journal of Chemotherapy
https://read.qxmd.com/read/38706262/pir-1919609-is-an-ideal-potential-target-for-reversing-platinum-resistance-in-ovarian-cancer
#63
JOURNAL ARTICLE
Ying Yan, Dan Tian, Bingbing Zhao, Zhuang Li, Zhijiong Huang, Kuina Li, Xiaoqi Chen, Lu Zhou, Yanying Feng, Zhijun Yang
PURPOSE: PIWI-interacting RNAs (piRNAs) are a type of noncoding small RNA that can interact with PIWI-like RNA-mediated gene silencing (PIWIL) proteins to affect biological processes such as transposon silencing through epigenetic effects. Recent studies have found that piRNAs are widely dysregulated in tumors and associated with tumor progression and a poor prognosis. Therefore, this study aimed to investigate the effect of piR-1919609 on the proliferation, apoptosis, and drug resistance of ovarian cancer cells...
2024: Technology in Cancer Research & Treatment
https://read.qxmd.com/read/38706130/discovery-of-2-6-naphthyridine-analogues-as-selective-fgfr4-inhibitors-for-hepatocellular-carcinoma
#64
JOURNAL ARTICLE
Heesook Oh, Jisook Kim, Seung Hyun Jung, Tae Hee Ha, Young Gil Ahn, Gibeom Nam, Kyeongwon Moon, Pargat Singh, In Su Kim
Hepatocellular carcinoma (HCC) is the most common type of liver cancer and is responsible for 90% of cases. Approximately 30% of patients diagnosed with HCC are identified as displaying an aberrant expression of fibroblast growth factor 19 (FGF19)-fibroblast growth factor receptor 4 (FGFR4) as an oncogenic-driver pathway. Therefore, the control of the FGF19-FGFR4 signaling pathway with selective FGFR4 inhibitors can be a promising therapy for the treatment of HCC. We herein disclose the design and synthesis of novel FGFR4 inhibitors containing a 2,6-naphthyridine scaffold...
May 5, 2024: Journal of Medicinal Chemistry
https://read.qxmd.com/read/38705564/flt3-selective-protac-enhanced-safety-and-increased-synergy-with-venetoclax-in-flt3-itd-mutated-acute-myeloid-leukemia
#65
JOURNAL ARTICLE
Yuxin Tan, Lilan Xin, Qian Wang, Rong Xu, Xiqin Tong, Guopeng Chen, Linlu Ma, Fuwei Yang, Hongqiang Jiang, Nan Zhang, Jinxian Wu, Xinqi Li, Xinyi Guo, Chao Wang, Haibing Zhou, Fuling Zhou
Acute myeloid leukemia (AML) patients carrying Fms-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) mutations often face a poor prognosis. While some FLT3 inhibitors have been used clinically, challenges such as short efficacy and poor specificity persist. Proteolytic targeting chimera (PROTAC), with its lower ligand affinity requirement for target proteins, offers higher and rapid targeting capability. Gilteritinib, used as the ligand for the target protein, was connected with different E3 ligase ligands to synthesize several series of PROTAC targeting FLT3-ITD...
May 3, 2024: Cancer Letters
https://read.qxmd.com/read/38705382/latent-transforming-growth-factor-%C3%AE-binding-protein-1-transforming-growth-factor-%C3%AE-1-complex-drives-antitumoral-effects-upon-erk5-targeting-in-melanoma
#66
JOURNAL ARTICLE
Alessandro Tubita, Alessio Menconi, Zoe Lombardi, Ignazia Tusa, Azucena Esparís-Ogando, Atanasio Pandiella, Tania Gamberi, Barbara Stecca, Elisabetta Rovida
Melanoma is the deadliest skin cancer, with a poor prognosis in advanced stages. Available treatments have improved the survival, although long-term benefits are still unsatisfactory. The mitogen-activated protein kinase ERK5 promotes melanoma growth, and ERK5 inhibition determines cellular senescence and the senescence-associated secretory phenotype. Here, latent-transforming growth factor β-binding protein 1 (LTBP1) mRNA was found to be upregulated in A375 and SK-Mel-5 BRAFV600E melanoma cells after ERK5 inhibition...
May 3, 2024: American Journal of Pathology
https://read.qxmd.com/read/38704915/the-eprs-atf4-coli-pathway-axis-is-a-potential-target-for-anaplastic-thyroid-carcinoma-therapy
#67
JOURNAL ARTICLE
Li Mi, Jiaye Liu, Yujie Zhang, Anping Su, Minghai Tang, Zhichao Xing, Ting He, Tao Wei, Zhihui Li, Wenshuang Wu
BACKGROUND: Anaplastic thyroid carcinoma (ATC) is recognized as the most aggressive and malignant form of thyroid cancer, underscoring the critical need for effective therapeutic strategies to curb its progression and improve patient prognosis. Halofuginone (HF), a derivative of febrifugine, has displayed antitumor properties across various cancer types. However, there is a paucity of published research focused on the potential of HF to enhance the clinical efficacy of treating ATC. OBJECTIVE: In this study, we thoroughly investigated the antitumor effects and mechanisms of HF in ATC, aiming to discover lead compounds for treating ATC and reveal novel therapeutic targets for ATC tumors...
April 28, 2024: Phytomedicine
https://read.qxmd.com/read/38704784/autogenous-graft-versus-collagen-matrices-for-peri-implant-soft-tissue-augmentation-a-systematic-review-and-network-meta-analysis
#68
REVIEW
Grazia Tommasato, Massimo Del Fabbro, Nadim Oliva, Shahnawaz Khijmatgar, Maria Gabriella Grusovin, Anton Sculean, Luigi Canullo
OBJECTIVE: The primary objective of this review is to compare autogenous soft tissue grafts (connective tissue graft - CTG and free gingival graft-FGG) with different type of matrices (acellular dermal matrix-ADM, xenograft collagen matrix-XCM, volume-stable collagen matrix-VCMX) used to increase peri-implant soft tissues. MATERIALS AND METHODS: A search on electronic databases was performed to identify randomized and non-randomized controlled trials (RCTs and CCTs, respectively) with either parallel or split-mouth design, and treating ≥ 10 patients...
May 5, 2024: Clinical Oral Investigations
https://read.qxmd.com/read/38704604/antileukemic-potential-of-methylated-indolequinone-mac681-through-immunogenic-necroptosis-and-parp1-degradation
#69
JOURNAL ARTICLE
Barbora Orlikova-Boyer, Anne Lorant, Sruthi Reddy Gajulapalli, Claudia Cerella, Michael Schnekenburger, Jin-Young Lee, Ji Yeon Paik, Yejin Lee, David Siegel, David Ross, Byung Woo Han, Thi Kim Yen Nguyen, Christo Christov, Hyoung Jin Kang, Mario Dicato, Marc Diederich
BACKGROUND: Despite advancements in chronic myeloid leukemia (CML) therapy with tyrosine kinase inhibitors (TKIs), resistance and intolerance remain significant challenges. Leukemia stem cells (LSCs) and TKI-resistant cells rely on altered mitochondrial metabolism and oxidative phosphorylation. Targeting rewired energy metabolism and inducing non-apoptotic cell death, along with the release of damage-associated molecular patterns (DAMPs), can enhance therapeutic strategies and immunogenic therapies against CML and prevent the emergence of TKI-resistant cells and LSC persistence...
May 4, 2024: Biomarker Research
https://read.qxmd.com/read/38704133/bet-inhibition-decreases-hmgcs2-and-sensitizes-resistant-pancreatic-tumors-to-gemcitabine
#70
JOURNAL ARTICLE
Aubrey L Miller, Samuel C Fehling, Rebecca B Vance, Dongquan Chen, Eric Josh Brown, M Iqbal Hossain, Eric O Heard, Shaida Andrabi, Hengbin Wang, Eddy S Yang, Donald J Buchsbaum, Robert C A M van Waardenburg, Susan L Bellis, Karina J Yoon
Efforts to develop targetable molecular bases for drug resistance for pancreatic ductal adenocarcinoma (PDAC) have been equivocally successful. Using RNA-seq and ingenuity pathway analysis we identified that the superpathway of cholesterol biosynthesis is upregulated in gemcitabine resistant (gemR) tumors using a unique PDAC PDX model with resistance to gemcitabine acquired in vivo. Analysis of additional in vitro and in vivo gemR PDAC models showed that HMG-CoA synthase 2 (HMGCS2), an enzyme involved in cholesterol biosynthesis and rate limiting in ketogenesis, is overexpressed in these models...
May 2, 2024: Cancer Letters
https://read.qxmd.com/read/38703660/liensinine-sensitizes-colorectal-cancer-cells-to-oxaliplatin-by-targeting-hif-1%C3%AE-to-inhibit-autophagy
#71
JOURNAL ARTICLE
Zhiqiang Feng, Shuai Zhang, Qiurong Han, Tianhao Chu, Huaqing Wang, Li Yu, Weihua Zhang, Jun Liu, Weizheng Liang, Jun Xue, Xueliang Wu, Chunze Zhang, Yijia Wang
BACKGROUND: Oxaliplatin is the most common chemotherapeutic agent for patients with colorectal cancer. However, its anti-cancer efficacy is restricted by drug resistance occurring through several mechanisms, including autophagy. Liensinine exerts a considerable anti-tumor effect and can regulate autophagy. Inhibition of autophagy is a strategy to reverse resistance to oxaliplatin. The aim of this study was to check if liensinine can enhance the therapeutic efficacy of oxaliplatin in colorectal cancer and if so, elucidate its mechanism...
April 22, 2024: Phytomedicine
https://read.qxmd.com/read/38703587/a-third-generation-psma-targeted-agent-211-at-yf2-synthesis-and-in-vivo-evaluation
#72
JOURNAL ARTICLE
Yutian Feng, Rebecca L Meshaw, Sean W Finch, Yongxiang Zheng, Il Minn, Ganesan Vaidyanathan, Martin G Pomper, Michael R Zalutsky
INTRODUCTION: Targeted α-particle therapy agents have shown promising responses in patients who have developed resistance to β- -particle emitting radionuclides, albeit off-target toxicity remains a concern. Astatine-211 emits only one α-particle per decay and may alleviate the toxicity from α-emitting daughter radionuclides. Previously, we developed the low-molecular-weight PSMA-targeted agent [211 At]L3-Lu that showed suitable therapeutic efficacy and was well tolerated in mice...
May 1, 2024: Nuclear Medicine and Biology
https://read.qxmd.com/read/38703241/targeting-bmal1-reverses-drug-resistance-of-acute-myeloid-leukemia-cells-and-promotes-ferroptosis-through-hmgb1-gpx4-signaling-pathway
#73
JOURNAL ARTICLE
Hong Zheng, Ting Wu, Zhi Lin, Dan Wang, Jing Zhang, Ting Zeng, Leping Liu, Jie Shen, Mingyi Zhao, Jia-Da Li, Minghua Yang
PURPOSE: Acute myeloid leukemia (AML) is a refractory hematologic malignancy that poses a serious threat to human health. Exploring alternative therapeutic strategies capable of inducing alternative modes of cell death, such as ferroptosis, holds great promise as a viable and effective intervention. METHODS: We analyzed online database data and collected clinical samples to verify the expression and function of BMAL1 in AML. We conducted experiments on AML cell proliferation, cell cycle, ferroptosis, and chemotherapy resistance by overexpressing/knocking down BMAL1 and using assays such as MDA detection and BODIPY 581/591 C11 staining...
May 4, 2024: Journal of Cancer Research and Clinical Oncology
https://read.qxmd.com/read/38702644/muc1-promotes-cervical-squamous-cell-carcinoma-through-erk-phosphorylation-mediated-regulation-of-itga2-itga3
#74
JOURNAL ARTICLE
Aiqin Zhao, Yunzhi Pan, Yingyin Gao, Zheng Zhi, Haiying Lu, Bei Dong, Xuan Zhang, Meiying Wu, Fenxia Zhu, Sufang Zhou, Sai Ma
In contrast to the decreasing trends in developed countries, the incidence and mortality rates of cervical squamous cell carcinoma in China have increased significantly. The screening and identification of reliable biomarkers and candidate drug targets for cervical squamous cell carcinoma are urgently needed to improve the survival rate and quality of life of patients. In this study, we demonstrated that the expression of MUC1 was greater in neoplastic tissues than in non-neoplastic tissues of the cervix, and cervical squamous cell carcinoma patients with high MUC1 expression had significantly worse overall survival than did those with low MUC1 expression, indicating its potential for early diagnosis of cervical squamous cell carcinoma...
May 3, 2024: BMC Cancer
https://read.qxmd.com/read/38702309/discovery-of-immunotherapy-targets-for-pediatric-solid-and-brain-tumors-by-exon-level-expression
#75
JOURNAL ARTICLE
Timothy I Shaw, Jessica Wagner, Liqing Tian, Elizabeth Wickman, Suresh Poudel, Jian Wang, Robin Paul, Selene C Koo, Meifen Lu, Heather Sheppard, Yiping Fan, Francis H O'Neill, Ching C Lau, Xin Zhou, Jinghui Zhang, Stephen Gottschalk
Immunotherapy with chimeric antigen receptor T cells for pediatric solid and brain tumors is constrained by available targetable antigens. Cancer-specific exons present a promising reservoir of targets; however, these have not been explored and validated systematically in a pan-cancer fashion. To identify cancer specific exon targets, here we analyze 1532 RNA-seq datasets from 16 types of pediatric solid and brain tumors for comparison with normal tissues using a newly developed workflow. We find 2933 exons in 157 genes encoding proteins of the surfaceome or matrisome with high cancer specificity either at the gene (n = 148) or the alternatively spliced isoform (n = 9) level...
May 3, 2024: Nature Communications
https://read.qxmd.com/read/38702301/focal-adhesion-kinase-yap-signaling-axis-drives-drug-tolerant-persister-cells-and-residual-disease-in-lung-cancer
#76
JOURNAL ARTICLE
Franziska Haderk, Yu-Ting Chou, Lauren Cech, Celia Fernández-Méndez, Johnny Yu, Victor Olivas, Ismail M Meraz, Dora Barbosa Rabago, D Lucas Kerr, Carlos Gomez, David V Allegakoen, Juan Guan, Khyati N Shah, Kari A Herrington, Oghenekevwe M Gbenedio, Shigeki Nanjo, Mourad Majidi, Whitney Tamaki, Yashar K Pourmoghadam, Julia K Rotow, Caroline E McCoach, Jonathan W Riess, J Silvio Gutkind, Tracy T Tang, Leonard Post, Bo Huang, Pilar Santisteban, Hani Goodarzi, Sourav Bandyopadhyay, Calvin J Kuo, Jeroen P Roose, Wei Wu, Collin M Blakely, Jack A Roth, Trever G Bivona
Targeted therapy is effective in many tumor types including lung cancer, the leading cause of cancer mortality. Paradigm defining examples are targeted therapies directed against non-small cell lung cancer (NSCLC) subtypes with oncogenic alterations in EGFR, ALK and KRAS. The success of targeted therapy is limited by drug-tolerant persister cells (DTPs) which withstand and adapt to treatment and comprise the residual disease state that is typical during treatment with clinical targeted therapies. Here, we integrate studies in patient-derived and immunocompetent lung cancer models and clinical specimens obtained from patients on targeted therapy to uncover a focal adhesion kinase (FAK)-YAP signaling axis that promotes residual disease during oncogenic EGFR-, ALK-, and KRAS-targeted therapies...
May 3, 2024: Nature Communications
https://read.qxmd.com/read/38701407/abbv-319-a-cd19-targeting-glucocorticoid-receptor-modulator-antibody-drug-conjugate-therapy-for-b-cell-malignancies
#77
JOURNAL ARTICLE
Chewei Anderson Chang, Ethan Emberley, Aloma L D'Souza, Weilong Zhao, Cormac Cosgrove, Karen E Parrish, Diya Mitra, Elmer Payson, Anatol Oleksijew, Paul Ellis, Luis Rodriguez, Ryan Duggan, Cara Hrusch, Loren Lasko, Wissam Assaily, Pingping Zheng, Wei Liu, Axel Hernandez, Kimberley McCarthy, Zhaomei Zhang, Geunbae Rha, Zhensheng Cao, Yingchun Li, Olivia Perng, Jos Campbell, Gloria Zhang, Tyler Scott Curran, Milan Bruncko, Christopher C Marvin, Adrian D Hobson, Michael McPherson, Tamar Uziel, Marybeth A Pysz, Xi Zhao, Alexander Bankovich, Joel Hayflick, Michael McDevitt, Kevin J Freise, Susan Morgan-Lappe, James W Purcell
Glucocorticoids are key components of the current standard-of-care regimens (e.g., R-CHOP, EPOCH-R, Hyper-CVAD) for treatment of B-cell malignancy. However, systemic glucocorticoid treatment is associated with several adverse events. CD19 displays restricted expression in normal B-cells and is up-regulated in B-cell malignancies. ABBV-319 is a CD19-targeting antibody-drug conjugate (ADC) engineered to reduce glucocorticoid-associated toxicities while possessing three distinct mechanisms of action (MOA) to increase therapeutic efficacy: (1) antibody-mediated delivery of glucocorticoid receptor modulator (GRM) payload to activate apoptosis, (2) inhibition of CD19 signaling, and (3) enhanced Fc-mediated effector function via afucosylation of the antibody backbone...
May 3, 2024: Blood
https://read.qxmd.com/read/38700824/circ_tmco3-inhibits-the-progression-of-cervical-cancer-by-activating-frmd6-expression-by-restraining-mir-1291
#78
JOURNAL ARTICLE
Xue Xue, Yixia Pan, Chen Li
Cervical cancer (CC) is one of the most common cancers that threaten the life of women. More and more circular RNAs (circRNAs) have been found to be maladjusted in tumor tissues. However, the mechanism of circ_TMCO3 in CC needs to be studied. In this study, quantitative real-time polymerase chain reaction (qRT-PCR), western blot, and immunohistochemistry (IHC) were used to detect the expressions of circ_TMCO3, miR-1291, and FERM domain-containing protein 6 (FRMD6). Cell viability, proliferation, apoptosis, migration, invasion, and protein level were detected via 3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2-H-tetrazolium bromide (MTT), 5-Ethynyl-2' -deoxyuridine (EdU), flow cytometry, transwell and western blot, respectively...
May 3, 2024: Reproductive Sciences
https://read.qxmd.com/read/38700808/retrospective-assessment-of-translational-pharmacokinetic-pharmacodynamic-modeling-performance-a-case-study-with-apitolisib-a-dual-pi3k-mtor-inhibitor
#79
JOURNAL ARTICLE
Anita Moein, Jin Y Jin, Matthew R Wright, Bruno Alicke, Harvey Wong
BACKGROUND AND OBJECTIVES: Despite significant progress in biomedical research, the rate of success in oncology drug development remains inferior to that of other therapeutic fields. Mechanistic models provide comprehensive understanding of the therapeutic effects of drugs, which is crucial for designing effective clinical trials. This study was performed to acquire a better understanding of PI3K-AKT-TOR pathway modulation and preclinical to clinical translational bridging for a specific compound, apitolisib (PI3K/mTOR inhibitor), by developing integrated mechanistic models...
May 3, 2024: Drugs in R&D
https://read.qxmd.com/read/38698344/patient-derived-castration-resistant-prostate-cancer-model-revealed-ctbp2-upregulation-mediated-by-oct1-and-androgen-receptor
#80
JOURNAL ARTICLE
Daisuke Obinata, Kenichi Takayama, Mitchell G Lawrence, Daigo Funakoshi, Makoto Hara, Birunthi Niranjan, Linda Teng, Renea A Taylor, Gail P Risbridger, Satoru Takahashi, Satoshi Inoue
BACKGROUND: Prostate cancer is dependent on androgen receptor (AR) signaling, and androgen deprivation therapy (ADT) has proven effective in targeting prostate cancer. However, castration-resistant prostate cancer (CRPC) eventually emerges. AR signaling inhibitors (ARSI) have been also used, but resistance to these agents develops due to genetic AR alterations and epigenetic dysregulation. METHODS: In this study, we investigated the role of OCT1, a member of the OCT family, in an AR-positive CRPC patient-derived xenograft established from a patient with resistance to ARSI and chemotherapy...
May 2, 2024: BMC Cancer
keyword
keyword
49477
4
5
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.